Answering these questions is of fundamental importance for verifying and advancing the emerging concept pointing to structurally distinct prion-like strains [89,102] of tau as a critical differentiating factor in AD and FTLD-tau development. The gene discussed is MAPT; the disease is Alzheimer disease.